ÂÜÀòÂÒÂ×

Ben Auspitz has worked in biotechnology for two decades as an entrepreneur, operator and investor. He has been involved in the funding and founding of more than 20 companies, which have currently generated six approved drugs.

Prior to IDRx, Ben was a partner at F-Prime Capital, where he focused on Series A and company formation. At F-Prime, Ben led first venture investments in Ultragenyx, Modis Therapeutics, REGENXBio, Symbiomix, Orchard Therapeutics, Precision Biosciences, Xilio Therapeutics and Atalanta Therapeutics, among others.

Ben holds a B.A. from Harvard University.